Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410–1416.

    CAS  PubMed  Google Scholar 

  2. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177–1184.

    CAS  PubMed  Google Scholar 

  3. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T . p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814–822.

    Article  CAS  PubMed  Google Scholar 

  4. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT . Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003; 10: 477–484.

    Article  CAS  PubMed  Google Scholar 

  5. Thornton PD, Gruszka-Westwood AM, Hamoudi RA, Atkinson S, Kaczmarek P, Morilla RM et al. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J 2004; 5: 47–54.

    Article  CAS  PubMed  Google Scholar 

  6. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92: 3963–3967.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Smardova J, Pavlova S, Koukalova H . Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast. Pathol Oncol Res 2002; 8: 245–251.

    Article  CAS  PubMed  Google Scholar 

  8. Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D et al. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 1996; 12: 813–818.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Grants NR8445-3, NR/8068-3, NR8443-3 and NR8448-3 provided by the Internal Grant Agency of the Ministry of Health of the Czech Republic, by the Research Proposal 0021622415 from the Ministry of Education of the Czech Republic and by the European Research Initiative on CLL (ERIC).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Trbusek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trbusek, M., Malcikova, J., Smardova, J. et al. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia 20, 1159–1161 (2006). https://doi.org/10.1038/sj.leu.2404195

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404195

This article is cited by

Search

Quick links